Immunological landscape and immunotherapy of hepatocellular carcinoma.
about
Recent advances in hepatocellular carcinoma therapy.Successful chemoimmunotherapy against hepatocellular cancer in a novel murine model.Tumor stage and primary treatment of hepatocellular carcinoma at a large tertiary hospital in China: A real-world study.Harms and benefits of adoptive immunotherapy for postoperative hepatocellular carcinoma: an updated reviewFoldable glycoprobes capable of fluorogenic crosslinking of biomacromoleculesAutologous transplantation of cytokine-induced killer cells as an adjuvant therapy for hepatocellular carcinoma in Asia: an update meta-analysis and systematic reviewImmunotherapeutic approaches for hepatocellular carcinomaTimely meta-analysis on the efficacy of adoptive immunotherapy for hepatocellular carcinoma patients after curative therapy.Relative Initial Weight Is Associated with Improved Survival without Altering Tumor Latency in a Translational Rat Model of Diethylnitrosamine-Induced Hepatocellular Carcinoma and Transarterial Embolization.Programmed death ligand 1 as an indicator of pre-existing adaptive immune responses in human hepatocellular carcinomaA novel multi-target RNAi adenovirus inhibits hepatoma cell proliferation, migration, and induction of angiogenesis.Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib.Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma.Blocking the CCL2-CCR2 Axis Using CCL2-Neutralizing Antibody Is an Effective Therapy for Hepatocellular Cancer in a Mouse Model.Clinical trials of antiangiogenic therapy for hepatocellular carcinoma.lnc-β-Catm elicits EZH2-dependent β-catenin stabilization and sustains liver CSC self-renewal.Systemic treatment for advanced hepatocellular carcinoma: the search of new agents to join sorafenib in the effective therapeutic armamentarium.Multifunctional microbeads for drug delivery in TACE.Distribution of tumor stage and initial treatment modality in patients with primary hepatocellular carcinoma.Serum albumin levels in relation to tumor parameters in hepatocellular carcinoma patients.Surface expression of anti-CD3scfv stimulates locoregional immunotherapy against hepatocellular carcinoma depending on the E1A-engineered human umbilical cord mesenchymal stem cells.1810011o10 Rik Inhibits the Antitumor Effect of Intratumoral CD8+ T Cells through Suppression of Notch2 Pathway in a Murine Hepatocellular Carcinoma Model.Getting the Skinny on CD4(+) T Cell Survival in Fatty Livers.Phase I clinical study of personalized peptide vaccination combined with radiotherapy for advanced hepatocellular carcinoma.A Natural CCR2 Antagonist Relieves Tumor-associated Macrophage-mediated Immunosuppression to Produce a Therapeutic Effect for Liver Cancer.Tumor-specific hepatic stellate cells (tHSCs) induces DIgR2 expression in dendritic cells to inhibit T cells.DlgR2 knockdown boosts dendritic cell activity and inhibits hepatocellular carcinoma tumor in-situ growth.Liver cancers with stem/progenitor-cell features - a rare chemotherapy-sensitive malignancy.Cancer vaccines and immunotherapeutic approaches in hepatobiliary and pancreatic cancers.Safety in treatment of hepatocellular carcinoma with immune checkpoint inhibitors as compared to melanoma and non-small cell lung cancer.Nanoparticle core stability and surface functionalization drive the mTOR signaling pathway in hepatocellular cell lines.Contradictory intrahepatic immune responses activated in high-load hepatitis C virus livers compared with low-load livers.The significance of intertumor and intratumor heterogeneity in liver cancer.Targets for immunotherapy of liver cancer.Hepatoma-intrinsic CCRK inhibition diminishes myeloid-derived suppressor cell immunosuppression and enhances immune-checkpoint blockade efficacy.B lymphocytes repress hepatic tumorigenesis but not development in Hras12V transgenic mice.Immunomodulation in hepatocellular cancer.High number of PD-1 positive intratumoral lymphocytes predict survival benefit of CIK cells for hepatocellular carcinoma patients.Development of a new patient-derived xenograft humanised mouse model to study human-specific tumour microenvironment and immunotherapy.Long non-coding RNA Lnc-Tim3 exacerbates CD8 T cell exhaustion via binding to Tim-3 and inducing nuclear translocation of Bat3 in HCC.
P2860
Q30236010-CE46AF6C-B284-4E50-8F4C-282F9ACB3D83Q30276134-E7F3FCEA-8A8F-4CF0-8A7D-9BD95FCCF179Q33566921-24197635-92C1-47D9-8FF9-28BE22BA6FEDQ33567018-FD6B031A-DB86-4B90-B6CB-6721BB4A0BDFQ33743814-05AC83D5-6054-4CC6-A2BA-3BE492B692B9Q33761739-8CC5E9F9-ECD1-434A-BC74-68F11759ED7BQ33779723-DBF7687C-CB32-49EF-B14A-8BEC24E40B3CQ36322143-BBD74D10-6E33-46CE-B0FA-D88472CA2335Q36369624-B1222E72-E9C1-46CE-B1C5-FC11B238F455Q37222152-CE0B4529-6408-4059-8066-24E581D0C131Q37628921-E227437C-65B3-455A-B050-F8F76E2FC90DQ37687133-6E397D36-0E36-4ED3-9474-F18589DE0C7CQ38722204-735FEB4E-38D5-427B-8E57-348A2225499DQ38726039-307D3F84-F329-49EE-91EC-6F055E1BAA93Q38743040-59F0B53E-177E-42D3-B0E5-BE0853DD53B9Q38767528-D3876FB4-F6E5-464E-8AA1-1319F39070B8Q38824017-8B0CBE0E-97FD-4698-8578-B766F1076D3FQ38843998-C40C5845-DAF4-42E9-8920-402C5F2DE2F3Q38979703-29A8E56D-2E4B-4D8B-A1DD-A703B44F16A5Q40061509-0A32BE27-B992-4193-8E00-F06D12612DD1Q40160910-86ED36B5-E033-4299-A82B-D0E50909849EQ40262828-464778DB-D098-47C6-BDCB-DC77FBDB5842Q40706956-8824FF99-2A8B-4639-A4F5-2934B31FEEBCQ41334725-D00D900C-1519-4070-8373-10A2DB2F2992Q41348794-636A32C8-C67A-49F6-8C90-4817FCB37241Q41549602-FC963E44-CFEC-47ED-963F-59185185E48BQ41549930-49560CA6-78F8-4D52-B210-C8B3768C06BCQ41709149-DC52A5AF-CBCC-41BE-BDED-1C2A90A1C582Q47109220-A03C1AD8-DA01-45FB-BB63-C5F9DA6ADE32Q47119885-9778288D-0A9B-4372-BE48-89036A6C4959Q47124020-5F1B1C5B-CB93-40FA-BDCD-CCD978214FAAQ47564662-8902411F-4135-4204-9CDF-C08CFC9A5750Q47750195-ABE6B775-2E6A-43BC-8AA9-D2243AA4AF8DQ47965755-EF13FD67-927E-4820-87C2-29A9B3978954Q48308089-64E9AE03-8834-4643-BBC9-0CB93CD11C6BQ48330501-284169AC-CF71-4B17-ABDF-5E12D677CD65Q52346985-359A7BAE-C3CC-4734-8EFB-08D8B93D2042Q52709378-888512BC-190C-4F7F-A584-70566D16D340Q52722792-3DF2FD8D-58A4-4B58-845D-B680A5A8506CQ55007862-B6623F59-24C2-4F7D-85EC-5EC6E70027A9
P2860
Immunological landscape and immunotherapy of hepatocellular carcinoma.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Immunological landscape and immunotherapy of hepatocellular carcinoma.
@en
type
label
Immunological landscape and immunotherapy of hepatocellular carcinoma.
@en
prefLabel
Immunological landscape and immunotherapy of hepatocellular carcinoma.
@en
P2860
P1476
Immunological landscape and immunotherapy of hepatocellular carcinoma.
@en
P2093
Ignacio Melero
P2860
P2888
P304
P356
10.1038/NRGASTRO.2015.173
P407
P577
2015-10-20T00:00:00Z
P6179
1006949208